August 29th 2025
Results from the phase 3 SAPPHIRE trial show significant improvements in motor function in children and adults with spinal muscular atrophy.
FDA Receives 2 Supplemental Biologics License Applications for Guselkumab for Pediatric Indications
December 3rd 2024If approved, the new indications include children 6 years and older with moderate to severe plaque psoriasis and children 5 years and older with active juvenile psoriatic arthritis.
Read More
Childhood Pneumococcal Vaccination Programs Indirectly Protect Adults From Pneumococcal Disease
November 29th 2024Pneumococcal disease incidence decreased in adults after pneumococcal vaccines began to be used in children due to indirect protection, with fewer adults found to carry the bacterium that causes disease.
Read More
RSV Preventative Monoclonal Antibody Could Reduce Disease Incidence in Preterm, Full-term Infants
November 6th 2024Clesrovimab reduced RSV-associated hospitalizations and RSV-associated lower respiratory infection hospitalizations by more than 84% and 90% in preterm and full-term infants, respectively.
Read More
Inotuzumab Ozogamicin in Pediatric Patients With Relapsed or Refractory B-Cell ALL
October 18th 2024This review discusses the significance of the FDA-approved drug inotuzumab ozogamicin in pediatric patients with acute lymphocytic leukemia (ALL) and relapsed/refractory (R/R) ALL, and the evolving therapeutic options in R/R ALL.
Read More
FDA Approves Sodium Oxybate to Treat Cataplexy or EDS in Pediatric Patients With Narcolepsy
Published: October 17th 2024 | Updated: October 17th 2024Patients aged 7 years and older can now be treated for their cataplexy or excessive daytime sleepiness with the extended-release oral formulation.
Read More